Talquetamab-Tgvs

Introduction Overview

Generic Name

talquetamab-tgvs

Brand Name

Talvey

Dosage Form

subcutaneous injection (3 mg/1.5 mL, 40 mg/mL)

Drug Class

Bispecific T-cell engagers (BiTE)

Pharmacokinetics

Absorption:
Talvey (talquetamab-tgvs) is administered via subcutaneous injection, allowing for slow and sustained absorption into the systemic circulation. The subcutaneous route facilitates gradual drug uptake through the lymphatic system, which contributes to prolonged systemic exposure with reduced peak plasma concentrations compared to intravenous administration. Pharmacokinetic studies have demonstrated that post-subcutaneous injection, therapeutic plasma concentrations are achieved with a dosing interval of once weekly or biweekly, maintaining effective target engagement and biological activity. Absorption may be influenced by factors such as injection site (abdomen, thigh, other subcutaneous sites), local blood flow, and patient-specific variables like body composition.

Distribution:
Talquetamab, being a large bispecific monoclonal antibody-derived molecule, predominantly remains within the vascular and interstitial compartments. Due to its molecular size and hydrophilic nature, it exhibits limited distribution into intracellular spaces or across tight biological barriers such as the blood-brain barrier. The volume of distribution approximates plasma volume plus extracellular fluid, consistent with typical antibody pharmacokinetics. Binding to the target antigens, GPRC5D on myeloma cells, and CD3 on T cells localized in bone marrow and peripheral tissues, influences tissue distribution. Additionally, binding to circulating T cells can act as a reservoir, potentially modulating pharmacodynamic responses.

Metabolism:
Talquetamab-tgvs, similar to other monoclonal antibodies, undergoes catabolic degradation primarily through proteolytic enzymes that break down the protein into smaller peptides and amino acids within the reticuloendothelial system and target tissues. Unlike small molecules metabolized via hepatic cytochrome P450 enzymes, talquetamab is not subject to liver enzyme-mediated metabolism, reducing risks of hepatic drug-drug interactions. Target-mediated drug disposition may occur whereby binding to CD3 and GPRC5D antigens influences catabolism rates. Immunogenicity could affect clearance if neutralizing antibodies develop. No active metabolites are formed; only peptide fragments result.

Elimination:
Elimination of talquetamab-tgvs follows typical monoclonal antibody clearance pathways, predominantly via cellular uptake and lysosomal degradation. The estimated half-life supports dosing intervals of weekly or biweekly administration, balancing efficacy and tolerability. Renal excretion is negligible due to the large molecular size. Eliminations rates may vary with tumor burden, expression levels of GPRC5D and CD3, and immune system status. Clinical pharmacokinetic evaluations showed a consistent elimination profile with no accumulation after repeated dosing. The safety monitoring includes assessment for cytokine release syndrome and neurological adverse effects which might correlate indirectly with pharmacokinetics and immune activation.

Dosage Forms

Available Dosage Forms:
Talvey is supplied as a subcutaneous injection in two vial strengths:
- Single-Dose Vial: 3 mg/1.5 mL (2 mg/mL)
- Single-Dose Vial: 40 mg/mL

Dosages for Adults and Adolescents:
Talvey is indicated for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy. The dosing regimen is initiated with a step-up dosing phase to mitigate risks of cytokine release syndrome (CRS) and neurologic adverse events. During this phase, incremental doses are administered:
- Step-Up Phase: Initial small doses are given over the first 2 to 3 injections.
- Treatment Phase: After step-up, maintenance dosing is either 405 μg/kg once weekly or 800 μg/kg every two weeks administered subcutaneously.

Specific Patient Populations:
- Due to the risk of CRS and neurologic toxicity, Talvey requires specialized monitoring and hospitalization for 48 hours post step-up doses.
- Patients with hepatic or renal impairment have not shown altered pharmacokinetics, but monitoring is advised.
- Talvey is contraindicated or used with caution in patients with active infections.
- Pregnant women are advised against treatment due to potential embryofetal toxicity; effective contraception is required for women of childbearing potential during treatment and for 3 months post last dose.
- Data on pediatric, geriatric, and breastfeeding populations remain limited; breastfeeding is contraindicated during treatment and for 3 months after discontinuation.

Mechanism Of Action

Talvey (talquetamab-tgvs) is a bispecific T-cell engager (BiTE) antibody construct that exerts its therapeutic effects through dual binding mechanisms. It simultaneously targets G protein-coupled receptor, class C group 5 member D (GPRC5D) on multiple myeloma cells and the CD3 receptor on cytotoxic T-cells. This bispecific binding brings T cells into close proximity with malignant myeloma cells, facilitating direct T cell-mediated cytotoxicity.

At the molecular level, Talvey binds with high affinity to GPRC5D, a receptor preferentially expressed on malignant plasma cells and minimally on normal tissues, providing tumor specificity. Concurrently, binding to the CD3 epsilon subunit on T lymphocytes activates the T cell receptor complex, triggering T cell activation, proliferation, and clonal expansion. Activated T cells then release cytolytic proteins such as perforin and granzymes, inducing apoptosis of the myeloma cells.

This mechanism circumvents the need for antigen presentation via major histocompatibility complex (MHC), allowing effective targeting even in immune-suppressive tumor microenvironments. Clinical studies have shown that Talvey’s engagement of T cells results in significant tumor cell killing and durable responses in heavily pretreated multiple myeloma patients.

Compared to similar bispecific antibodies, such as Tecvayli which targets BCMA on myeloma cells, Talvey’s unique targeting of GPRC5D offers an alternative pathway for immune-mediated myeloma eradication. Research continues to explore combinatorial regimens exploiting Talvey’s mechanism to optimize clinical outcomes and manage resistance.

Pharmacological Actions

Bispecific engagement of T cells via CD3 receptor and multiple myeloma cells via GPRC5D receptor.
Activation and proliferation of cytotoxic T lymphocytes enhancing immune-mediated tumor cell killing.
Induction of apoptosis in myeloma cells through release of perforin and granzymes by T cells.
Tumor-targeted cellular cytotoxicity independent of MHC antigen presentation.
Modulation of tumor microenvironment favoring anti-cancer immune responses.
Potential reduction in tumor burden and disease progression in refractory multiple myeloma.
Minimal off-target cytotoxic effects due to selective GPRC5D expression on malignant plasma cells.
Ability to overcome resistance mechanisms to proteasome inhibitors and monoclonal antibodies.
Sustained immune activation contributing to durable clinical responses.
Immunomodulatory effects possibly augmenting concurrent therapeutic agents.

Therapeutic Or Clinical Uses

Treatment of adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.
Therapeutic option for patients whose multiple myeloma has progressed despite prior treatments.
Use in heavily pretreated multiple myeloma patients with limited alternative effective treatments.
Part of advanced immunotherapy for hematologic malignancies targeting tumor antigen and T cells simultaneously.
Management of patients unsuitable or refractory to CAR T-cell therapy or other bispecific antibodies.
Potential component in combination regimens with other antimyeloma agents.
Utilized under Risk Evaluation and Mitigation Strategy (REMS) programs due to specific safety risks.
Treatment administered in specialized oncology centers with expertise in managing immunotherapy toxicities.
Option for prolonging progression-free survival and improving quality of life in refractory multiple myeloma.
Addressing unmet needs in multiple myeloma with novel immune-based targeted therapy.

Side Or Adverse Effects

Altered or decreased sense of taste (dysgeusia).
Dysphagia (trouble swallowing) and dry mouth (xerostomia).
Gastrointestinal adverse events including diarrhea and weight loss.
Musculoskeletal symptoms such as muscle and joint pain (myalgias and arthralgias).
General fatigue and malaise (feeling very tired).
Nail disorders including abnormalities of fingernails and toenails.
Dermatologic effects such as dry skin and dryness of mucous membranes.
Infections involving upper respiratory tract including fever, nose, sinus, or throat infections.
Serious hypersensitivity reactions including anaphylaxis, manifested by hives, facial swelling, airway constriction, or breathing difficulty.
Cytokine release syndrome (CRS) characterized by fever, chills, hypotension, dyspnea, confusion, gastrointestinal symptoms, and tachyarrhythmias.
Immune suppression leading to increased susceptibility to bacterial, viral, or fungal infections; potential for fatal infections.
Mouth mucosal toxicities such as oral sores and ulcers.
Skin reactions including rash, redness, and erythematous bumps.
Hematologic toxicities such as neutropenia, anemia, thrombocytopenia leading to fever, bleeding, bruising, pallor, and fatigue.
Neurologic adverse effects including headache, tremors, muscle rigidity, confusion, seizures, sensory disturbances, motor weakness, and changes in cognitive function.
Elevations in liver enzymes or clinical hepatotoxicity signs like jaundice, abdominal pain, dark urine, and pruritus.

Precautions

Hospitalization for at least 48 hours after each step-up dose to monitor for cytokine release syndrome and neurologic toxicity.
Avoid driving or operating heavy machinery during treatment and for 48 hours post step-up dosing or when experiencing neurologic symptoms.
Close monitoring for signs and symptoms of CRS including fever, hypotension, respiratory distress, and altered mental status.
Immediate reporting of potential neurologic symptoms such as confusion, seizures, weakness, or speech difficulties.
Assessment and management of infections prior to and during therapy due to immunosuppression risk.
Pregnancy testing before initiation and effective contraception during treatment and for 3 months afterward due to potential fetal harm.
Avoid breastfeeding during treatment and for at least 3 months after the final dose due to unknown excretion in breast milk.
Regular hematologic monitoring to detect cytopenias early and manage accordingly.
Temporary or permanent discontinuation of therapy may be required upon severe adverse events.
Patient education regarding signs and symptoms of serious adverse effects and necessity for prompt medical attention.
Evaluation of baseline hepatic and renal function and ongoing monitoring.
Caution in patients with pre-existing neurologic disorders or compromised immune status.
Use under REMS program ensuring controlled distribution and enhanced safety monitoring.
Concomitant use of other immunosuppressive agents requires careful consideration and monitoring.
Monitoring for infusion or injection site reactions even with subcutaneous administration.

Warnings

Risk of severe or life-threatening cytokine release syndrome (CRS) which can occur after any dose, particularly during the step-up dosing phase.
Potential for serious neurologic toxicities including seizures, encephalopathy, confusion, tremors, and muscle weakness.
Serious and fatal infections may occur due to immunosuppression; prompt diagnosis and treatment are critical.
Hypersensitivity reactions, including anaphylaxis, can occur; emergency medical intervention must be readily available.
Use is restricted to healthcare settings with appropriate monitoring resources under a REMS program due to severe risks.
Discontinue or modify dose in case of severe or persistent CRS or neurologic events.
Pregnancy risk: Talquetamab may cause fetal harm based on animal data; avoid use in pregnant women.
Breastfeeding is contraindicated due to unknown risks to the infant.
Impairment in consciousness or neurologic function contraindicates use of machinery or driving.
Patients must carry a Patient Wallet Card describing symptomatology of CRS and neurologic problems for emergency identification.
Concomitant administration with live vaccines should be avoided due to immunosuppression.
Close clinical observation required during initial treatment period to quickly manage acute toxicities.
Delayed onset of some neurologic adverse effects - vigilance beyond immediate dosing periods is necessary.
Risk factors such as high tumor burden might increase severity of CRS and must be evaluated pre-treatment.
Drug discontinuation may be necessitated by life-threatening adverse reactions.

Contraindication

Known hypersensitivity to talquetamab-tgvs or any of its excipients including edetate disodium, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, or Water for Injection, USP.
Active, uncontrolled infection at the time of planned therapy initiation.
Concurrent participation in another investigational drug study due to potential unknown interactions and increased toxicity risk.
Severe or uncontrolled neurologic disorders that would complicate assessment or exacerbate treatment-related neurotoxicity.
Pregnant women due to potential teratogenicity and fetal harm.
Patients unable to comply with required monitoring and hospitalization due to CRS and neurologic risks.
Known severe hepatic impairment until further pharmacokinetic and safety data are available.
Patients with immunologic or hematological conditions that could worsen with further immunomodulation unless benefits outweigh risks.
History of severe anaphylactic reactions to monoclonal antibody therapies.
Use during breastfeeding due to unknown risks to neonates.
Simultaneous treatment with other T-cell engaging bispecific antibodies without clear clinical indication or supervision.
Recipients of live or live-attenuated vaccines during or within a defined period before talquetamab treatment.
Contraindicated in patients with severe cardiac instability where rapid adverse events cannot be managed.
Patients with severe thrombocytopenia or bleeding disorders may be contraindicated due to injection site bleeding risks.
Known active central nervous system malignancy or metastasis without prior adequate control.

Drug Interactions

Potential additive immunosuppression when combined with other immunomodulatory or cytotoxic agents, increasing infection risk.
No significant metabolism via cytochrome P450 pathways, so low potential for classic pharmacokinetic drug interactions.
Concomitant use with systemic corticosteroids may attenuate immune activation and possibly reduce therapeutic effect.
Drugs that alter T-cell function or counts may influence talquetamab efficacy and toxicity profiles.
Vaccines, especially live vaccines, may have decreased efficacy and increased risk of infection when administered concurrently.
Interactions with antiviral, antifungal, or antibacterial agents require vigilance, especially concerning infection prophylaxis.
Potential interaction with other biologics targeting immune checkpoints or T cell pathways.
Drugs causing QT prolongation should be used cautiously due to risk of additive cardiovascular toxicity in severely ill patients.
Pharmacodynamic interactions with agents causing cytokine induction or suppression may alter toxicity presentation.
No known interactions with common over-the-counter medications or herbal supplements have been established but caution advised.
Concomitant administration with other bispecific T-cell engager antibodies requires monitoring for overlapping toxicities.
No dose adjustment recommendations currently available for concomitant medications; clinical judgment advised.
Potential interaction with anticoagulants requiring monitoring of bleeding risk during subcutaneous injections.
Avoid abrupt discontinuation of concomitant immunosuppressants without clinical oversight.
Patients should provide comprehensive medication history including vitamins and herbal supplements due to unknown effects.

Preparations Of The Drug

Talvey is provided as a sterile, preservative-free, single-dose vial for subcutaneous injection.
Available vial strengths include 3 mg/1.5 mL (2 mg/mL concentration) and 40 mg/mL formulation.
Inactive ingredients include edetate disodium, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, and Water for Injection, USP.
Vials are intended for single use only; any unused portion must be discarded.
Preparation requires aseptic technique and proper dilution instructions as per prescribing information.
Should be stored refrigerated at 2°C to 8°C (36°F to 46°F) and protected from light; do not freeze.
Allow the vial to reach room temperature prior to administration.
No shaking or agitation to avoid protein denaturation.
Reconstitution or dilution beyond vial content is not typically required; follow specific product instructions.
Administration is via subcutaneous injection, predominantly in the abdomen or thigh, rotated injection sites recommended.
Healthcare providers preparing Talvey are advised to follow institutional guidelines for handling biologic agents.
Disposal of used vials and needles must comply with biohazard and pharmaceutical waste regulations.
Packaging includes a Patient Wallet Card detailing safety information and emergency symptoms.
Special handling precautions include storage and transport under controlled temperature to maintain stability.
The preparation process includes monitoring for particulate matter and discoloration before use.